Developing nucleoside tailoring strategies against SARS-CoV-2 via ribonuclease targeting chimera
In response to the urgent need for potent severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) therapeutics, this study introduces an innovative nucleoside tailoring strategy leveraging ribonuclease targeting chimeras. By seamlessly integrating ribonuclease L recruiters into nucleosides, we address RNA recognition challenges and effectively inhibit severe acute respiratory syndrome coronavirus 2 replication in human cells. Notably, nucleosides tailored at the ribose 2'-position outperform those modified at the nucleobase. Our in vivo validation using hamster models further bolsters the promise of this nucleoside tailoring approach, positioning it as a valuable asset in the development of innovative antiviral drugs.
| Medienart: |
E-Artikel |
|---|
| Erscheinungsjahr: |
2024 |
|---|---|
| Erschienen: |
2024 |
| Enthalten in: |
Zur Gesamtaufnahme - volume:10 |
|---|---|
| Enthalten in: |
Science advances - 10(2024), 15 vom: 12. Apr., Seite eadl4393 |
| Sprache: |
Englisch |
|---|
| Beteiligte Personen: |
Min, Yuanqin [VerfasserIn] |
|---|
| Links: |
|---|
| Themen: |
Antiviral Agents |
|---|
| Anmerkungen: |
Date Completed 12.04.2024 Date Revised 25.04.2024 published: Print-Electronic Citation Status MEDLINE |
|---|
| doi: |
10.1126/sciadv.adl4393 |
|---|
| funding: |
|
|---|---|
| Förderinstitution / Projekttitel: |
|
| PPN (Katalog-ID): |
NLM370879538 |
|---|
| LEADER | 01000caa a22002652 4500 | ||
|---|---|---|---|
| 001 | NLM370879538 | ||
| 003 | DE-627 | ||
| 005 | 20240425233730.0 | ||
| 007 | cr uuu---uuuuu | ||
| 008 | 240411s2024 xx |||||o 00| ||eng c | ||
| 024 | 7 | |a 10.1126/sciadv.adl4393 |2 doi | |
| 028 | 5 | 2 | |a pubmed24n1386.xml |
| 035 | |a (DE-627)NLM370879538 | ||
| 035 | |a (NLM)38598625 | ||
| 040 | |a DE-627 |b ger |c DE-627 |e rakwb | ||
| 041 | |a eng | ||
| 100 | 1 | |a Min, Yuanqin |e verfasserin |4 aut | |
| 245 | 1 | 0 | |a Developing nucleoside tailoring strategies against SARS-CoV-2 via ribonuclease targeting chimera |
| 264 | 1 | |c 2024 | |
| 336 | |a Text |b txt |2 rdacontent | ||
| 337 | |a ƒaComputermedien |b c |2 rdamedia | ||
| 338 | |a ƒa Online-Ressource |b cr |2 rdacarrier | ||
| 500 | |a Date Completed 12.04.2024 | ||
| 500 | |a Date Revised 25.04.2024 | ||
| 500 | |a published: Print-Electronic | ||
| 500 | |a Citation Status MEDLINE | ||
| 520 | |a In response to the urgent need for potent severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) therapeutics, this study introduces an innovative nucleoside tailoring strategy leveraging ribonuclease targeting chimeras. By seamlessly integrating ribonuclease L recruiters into nucleosides, we address RNA recognition challenges and effectively inhibit severe acute respiratory syndrome coronavirus 2 replication in human cells. Notably, nucleosides tailored at the ribose 2'-position outperform those modified at the nucleobase. Our in vivo validation using hamster models further bolsters the promise of this nucleoside tailoring approach, positioning it as a valuable asset in the development of innovative antiviral drugs | ||
| 650 | 4 | |a Journal Article | |
| 650 | 7 | |a Nucleosides |2 NLM | |
| 650 | 7 | |a Ribonucleases |2 NLM | |
| 650 | 7 | |a EC 3.1.- |2 NLM | |
| 650 | 7 | |a Antiviral Agents |2 NLM | |
| 700 | 1 | |a Xiong, Wei |e verfasserin |4 aut | |
| 700 | 1 | |a Shen, Wei |e verfasserin |4 aut | |
| 700 | 1 | |a Liu, Xingyu |e verfasserin |4 aut | |
| 700 | 1 | |a Qi, Qianqian |e verfasserin |4 aut | |
| 700 | 1 | |a Zhang, Yuanyuan |e verfasserin |4 aut | |
| 700 | 1 | |a Fan, Ruochen |e verfasserin |4 aut | |
| 700 | 1 | |a Fu, Fang |e verfasserin |4 aut | |
| 700 | 1 | |a Xue, Heng |e verfasserin |4 aut | |
| 700 | 1 | |a Yang, Hang |e verfasserin |4 aut | |
| 700 | 1 | |a Sun, Xiulian |e verfasserin |4 aut | |
| 700 | 1 | |a Ning, Yunjia |e verfasserin |4 aut | |
| 700 | 1 | |a Tian, Tian |e verfasserin |4 aut | |
| 700 | 1 | |a Zhou, Xiang |e verfasserin |4 aut | |
| 773 | 0 | 8 | |i Enthalten in |t Science advances |d 2015 |g 10(2024), 15 vom: 12. Apr., Seite eadl4393 |w (DE-627)NLM247717614 |x 2375-2548 |7 nnns |
| 773 | 1 | 8 | |g volume:10 |g year:2024 |g number:15 |g day:12 |g month:04 |g pages:eadl4393 |
| 856 | 4 | 0 | |u http://dx.doi.org/10.1126/sciadv.adl4393 |3 Volltext |
| 912 | |a GBV_USEFLAG_A | ||
| 912 | |a GBV_NLM | ||
| 951 | |a AR | ||
| 952 | |d 10 |j 2024 |e 15 |b 12 |c 04 |h eadl4393 | ||